Navigation Links
Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
Date:10/26/2009

eting approvals and to generate commercial sales. We are vigilant about upholding our industry leadership position in siRNA R&D by protecting our pipeline with an aggressive and comprehensive approach to intellectual property generation and management. . We are also focused on broadening our intellectual property estate to further protect and enhance the value of our product pipeline."

About the PF-4523655 (RTP801i-14) Clinical Program

PF-4523655 (RTP801i-14) is a synthetic, siRNA molecule designed to inhibit the expression of Quark's proprietary target, RTP801. The product candidate is licensed to Pfizer on an exclusive worldwide basis. Quark discovered RTP801 using its BiFAR(TM) target discovery platform, which identifies clinically relevant genes and proteins that are critical to reversing a given disease phenotype when inhibited. The Company owns a family of patents covering the RTP801 gene and protein sequences, specific antibodies, and gene inhibition across different disease indications.

The ongoing Phase II study is a prospective, randomized, multi-center, dose-ranging study is designed to evaluate the safety and efficacy of PF-4523655 versus laser therapy in 160 patients with DME. In this study, patients are randomized to receive intravitreal injections of one of three dose levels of PF-4523655, or laser therapy. Therapeutic effect will be evaluated by assessing visual acuity and retinal morphology.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 According to a ... (Moist Heat, Dry Heat, Ethylene Oxide, Filtration, E-beam, Gamma), Services ... (Hospitals, Pharmaceuticals) - Global Forecast to 2020", published by MarketsandMarkets, ... 6.1 Billion by 2020, at a CAGR of 7.6%.from 2015 ... market data T ables and 37 ...
(Date:7/31/2015)... and SAN DIEGO , July 31, ... company Eisai Co., Ltd. (Headquarters: Tokyo ... and Halozyme Therapeutics, Inc. (Headquarters: San Diego, ... Torley , "NASDAQ: HALO") have signed a clinical collaboration ... ® , "eribulin") in combination with Halozyme,s investigational drug ...
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... highlights: , Sales in local currency increased ... Reported sales decreased 4% as currency reduced sales growth ... per diluted share as reported (EPS) were $2.73, compared ... $2.80 , an increase of 9% over the ...
Breaking Medicine Technology:Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14
... , Feb. 4 Accuray Incorporated (Nasdaq: ARAY ), ... for the second quarter of fiscal year 2010, ended December 31, ... reported total revenue of $57.3 million , compared to the second ... , Accuray reported a net loss for the second quarter of fiscal ...
... , , ATLANTA , Feb. ... for Economic and Clinical Health (HITECH) Act, Elekta has expanded its ... advantage of the financial incentives available from the federal government. These ... certified EMR systems who are able to demonstrate meaningful use. , ...
Cached Medicine Technology:Accuray Announces Results for Second Quarter Fiscal 2010 2Accuray Announces Results for Second Quarter Fiscal 2010 3Accuray Announces Results for Second Quarter Fiscal 2010 4Accuray Announces Results for Second Quarter Fiscal 2010 5Accuray Announces Results for Second Quarter Fiscal 2010 6Accuray Announces Results for Second Quarter Fiscal 2010 7Accuray Announces Results for Second Quarter Fiscal 2010 8Accuray Announces Results for Second Quarter Fiscal 2010 9Accuray Announces Results for Second Quarter Fiscal 2010 10Accuray Announces Results for Second Quarter Fiscal 2010 11Accuray Announces Results for Second Quarter Fiscal 2010 12Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines 2Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines 3
(Date:8/1/2015)... Humble, TX (PRWEB) , ... August 01, 2015 , ... ... common concern among both men and women often causing pain and discomfort. Those who ... to this circulatory problem, and Northeast Houston Vein Center is doing what it can ...
(Date:8/1/2015)... New York, NY (PRWEB) , ... August 01, 2015 , ... ... Black Vine cyberespionage group , who are thought to have been behind the attack ... Among the topics covered were zero day exploits, watering hole attacks and spear phishing ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... High Times magazine. What are the STASH awards? The Significant Technological Achievements ... by the cannabis-cultivation community as well as tried-and-true products that have stood the ...
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
(Date:7/31/2015)... ... 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of ... Aesthetics released this new applicator in the United States as an upgrade to the ... The original applicator required a 2 hour treatment time. The new CoolSmooth ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... snore when they are pregnant may be at risk of ... when they give birth. Around 10% of pregnant women suffer ... lead to injury or even death in the mother and ... by resting or with medication. But drugs may put the ...
... pregnancy are predisposed to experimenting with tobacco at a ... had experimented with cigarettes in a survey, the majority ... at the University of Pittsburgh say the link may ... tobacco smoke while in the womb. Earlier studies have ...
... and Druggists Association (APCDA) has decided to help its ... is in the process of developing a software, which ... also procure the computers in bulk in order to ... interested in joining the campaign. The efforts are meant ...
... An Australian research team has discovered a way of preventing ... from the John Curtin School of Medical Research have found ... of viruses to escape from infected cells. This could develop ... found a drug that blocks the channels HIV may use ...
... buy a gas mask at the nearest army surplus store, take ... them -- most of it is not good. One could never ... at all times. //Even if you could stand to do that, ... likelihood that wearing the mask would prevent contamination. ...
... more likely to suffer from behavioural problems, a major ... hormone not only boosted growth in children, but also ... researcher Dr Derick Beens, professor of psychiatry and pediatrics ... this work demonstrates that all very short children need ...
Cached Medicine News:Health News:Snoring could be a warning 2Health News:Pregnant smokers could harm their child 2Health News:Drugs to stop burgeon of HIV 2
Provides outstanding patient warming and safety throughout the hospital and is nearly half the size and one-third the weight of earlier units....
The SnuggleWarm Convective Warming provides the technology and the tools to effectively enhance the quality of patient care....
The product, which is comprised of a non-intrusive panty-liner, offers a simple to use classification tool that uses color identification for interpretation of the results....
The Affirm™ VPIII tests RNA probe technology offers a dependable, rapid means toward early identification and treatment of patients suffering from these pathogens....
Medicine Products: